MX2022005976A - Compuestos antagonistas de receptores de adenosina. - Google Patents
Compuestos antagonistas de receptores de adenosina.Info
- Publication number
- MX2022005976A MX2022005976A MX2022005976A MX2022005976A MX2022005976A MX 2022005976 A MX2022005976 A MX 2022005976A MX 2022005976 A MX2022005976 A MX 2022005976A MX 2022005976 A MX2022005976 A MX 2022005976A MX 2022005976 A MX2022005976 A MX 2022005976A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- compositions
- adenosine receptor
- receptor
- receptor antagonist
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 229940121359 adenosine receptor antagonist Drugs 0.000 title 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 101150007969 ADORA1 gene Proteins 0.000 abstract 2
- 101150051188 Adora2a gene Proteins 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190149117A KR20210061202A (ko) | 2019-11-19 | 2019-11-19 | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| PCT/IB2020/000971 WO2021099838A1 (en) | 2019-11-19 | 2020-11-19 | Adenosine receptor antagonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005976A true MX2022005976A (es) | 2022-08-18 |
Family
ID=75980093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005976A MX2022005976A (es) | 2019-11-19 | 2020-11-19 | Compuestos antagonistas de receptores de adenosina. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12606564B2 (https=) |
| EP (1) | EP4061817A4 (https=) |
| JP (2) | JP7681616B2 (https=) |
| KR (3) | KR20210061202A (https=) |
| CN (2) | CN116425756B (https=) |
| AU (2) | AU2020386189B2 (https=) |
| BR (2) | BR122023020015A2 (https=) |
| CA (1) | CA3158731A1 (https=) |
| CL (1) | CL2022001307A1 (https=) |
| IL (1) | IL293107A (https=) |
| MX (1) | MX2022005976A (https=) |
| PH (1) | PH12022551223A1 (https=) |
| TW (3) | TWI850492B (https=) |
| WO (3) | WO2021099832A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11806350B2 (en) * | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TW202508599A (zh) * | 2023-05-19 | 2025-03-01 | 南韓商尹諾衛醫藥有限公司 | 用於神經保護或治療α突觸核蛋白及/或神經發炎相關疾病的化合物 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025170158A1 (ko) * | 2024-02-08 | 2025-08-14 | 아이리드비엠에스 주식회사 | Cxcr7 수용체 조절제 및 이의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000507552A (ja) * | 1996-03-26 | 2000-06-20 | デュポン ファーマシューティカルズ カンパニー | アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体 |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| PL337888A1 (en) * | 1997-07-03 | 2000-09-11 | Du Pont Pharm Co | Imidazoprimidines and imidazopyridines for use in treating neurological disorders |
| US6841549B1 (en) * | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| GB0100623D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| GB0100621D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VI |
| GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| ATE520694T1 (de) | 2001-11-09 | 2011-09-15 | Gilead Palo Alto Inc | A2b-adenosinrezeptorantagonisten |
| US20060128956A1 (en) * | 2003-04-21 | 2006-06-15 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (Purin-6-yl) amino acid and production method thereof |
| US8557830B2 (en) * | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2011050160A1 (en) | 2009-10-22 | 2011-04-28 | Biogen Idec Ma Inc. | Pharmaceuticals, compositions and methods of making and using the same |
| JP7337502B2 (ja) | 2015-09-16 | 2023-09-04 | ロクソ オンコロジー， インコーポレイテッド | がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体 |
| DE102017125533A1 (de) | 2017-10-31 | 2019-05-02 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | 4-(Furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amin-Derivate und deren Verwendung |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP4368184A3 (en) | 2019-11-19 | 2024-07-31 | Modag GmbH | Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein |
| AU2020389474B2 (en) | 2019-11-19 | 2026-03-12 | Clariant International Ltd | Solvates of abscisic acid and liquid compositions containing abscisic acid |
| US11806350B2 (en) * | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
-
2019
- 2019-11-19 KR KR1020190149117A patent/KR20210061202A/ko active Pending
-
2020
- 2020-11-19 IL IL293107A patent/IL293107A/en unknown
- 2020-11-19 AU AU2020386189A patent/AU2020386189B2/en active Active
- 2020-11-19 CN CN202211456336.XA patent/CN116425756B/zh active Active
- 2020-11-19 EP EP20890594.3A patent/EP4061817A4/en active Pending
- 2020-11-19 MX MX2022005976A patent/MX2022005976A/es unknown
- 2020-11-19 BR BR122023020015-2A patent/BR122023020015A2/pt unknown
- 2020-11-19 CA CA3158731A patent/CA3158731A1/en active Pending
- 2020-11-19 WO PCT/IB2020/000948 patent/WO2021099832A2/en not_active Ceased
- 2020-11-19 WO PCT/IB2020/000970 patent/WO2021099837A1/en not_active Ceased
- 2020-11-19 BR BR112022009487A patent/BR112022009487A2/pt unknown
- 2020-11-19 WO PCT/IB2020/000971 patent/WO2021099838A1/en not_active Ceased
- 2020-11-19 JP JP2022554968A patent/JP7681616B2/ja active Active
- 2020-11-19 CN CN202080080922.1A patent/CN114829363B/zh active Active
- 2020-11-19 PH PH1/2022/551223A patent/PH12022551223A1/en unknown
- 2020-11-19 KR KR1020227020600A patent/KR102749480B1/ko active Active
- 2020-11-19 US US17/777,881 patent/US12606564B2/en active Active
- 2020-11-19 TW TW109140608A patent/TWI850492B/zh active
- 2020-11-19 KR KR1020247033262A patent/KR102752564B1/ko active Active
- 2020-11-19 TW TW109140607A patent/TW202132304A/zh unknown
- 2020-11-19 TW TW112125972A patent/TWI851336B/zh active
-
2022
- 2022-05-18 CL CL2022001307A patent/CL2022001307A1/es unknown
-
2023
- 2023-05-09 AU AU2023202886A patent/AU2023202886B2/en active Active
-
2025
- 2025-05-12 JP JP2025079712A patent/JP2025120182A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551223A1 (en) | Adenosine receptor antagonist compounds | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| JOP20190151A1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| TN2010000040A1 (en) | 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| AU2018284960A1 (en) | AADC polynucleotides for the treatment of Parkinson's disease | |
| UA104849C2 (uk) | 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| EP2576549A4 (en) | Bicyclic Heteroarylkinase Inhibitors and Methods of Use | |
| MX394094B (es) | PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS. | |
| PH12016502168B1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| MX2018012211A (es) | Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| IL147271A0 (en) | Compounds that bind her2 | |
| AU2016249140A8 (en) | Anti-PACAP antibodies and uses thereof | |
| MX388912B (es) | Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos | |
| MX2018012208A (es) | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. | |
| MY198880A (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| CO2023007617A2 (es) | Prevención y/o tratamiento de enfermedades del snc | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| WO2020061106A3 (en) | Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease | |
| EP4233871A3 (en) | Inhibiting the transient receptor potential a1 ion channel |